Comments on: Biocon Q2FY24 Revenue at Rs 3,620 Cr, Up 52%; Biosimilars Up 97%; Research Services Up 18% EBITDA at Rs 900 Cr, Up 68%; Core EBITDA at Rs 1,100 Cr, Up 35% Net Profit at Rs 126 Cr, Up 168%

Comments on: Biocon Q2FY24 Revenue at Rs 3,620 Cr, Up 52%; Biosimilars Up 97%; Research Services Up 18% EBITDA at Rs 900 Cr, Up 68%; Core EBITDA at Rs 1,100 Cr, Up 35% Net Profit at Rs 126 Cr, Up 168% https://galleryrevieweurope.com/european-art/biocon-q2fy24-revenue-at-rs-3620-cr-up-52-biosimilars-up-97-research-services-up-18-ebitda-at-rs-900-cr-up-68-core-ebitda-at-rs-1100-cr-up-35-net-profit-at-rs-126-cr-up-168/ Fri, 10 Nov 2023 12:05:55 +0000 hourly 1